Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis.

Thrombosis research - 1 Mar 2022

Soudet Simon, Le Roy Gaelle, Cadet Estelle, Michaud Audrey, Morel Pierre, Marolleau Jean Pierre, Sevestre Marie Antoinette

Abstract excerpt

BACKGROUND: Thrombosis is the main complication in myeloproliferative neoplasms (MPN). A JAK2V617F mutation has been shown to be a risk factor for thrombosis. The implication of other risk factors alongside a mutation allele burden needs to be clarified (Trifa et al., 2018; Borowczyk et al., 2015). OBJECTIVE: Our aim was to investigate the role of the JAK2 mutation allele burden in the risk of cardiovascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Alleles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Thrombosis

Share to Venous Thrombosis

Source

Identifiers

PMID: 35051830
DOI: 10.1016/j.thromres.2022.01.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis.PMID 35051830Read ↗

Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasmsSemantic proximity Read ↗

No Differences in Outcomes Between JAK2 V617F-Positive Patients with Variant Allele Fraction < 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis.Semantic proximity Read ↗

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.Semantic proximity Read ↗

High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.Semantic proximity Read ↗

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burdenSemantic proximity Read ↗

JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemiaSemantic proximity Read ↗

Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.Semantic proximity Read ↗

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.Semantic proximity Read ↗

[Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].Semantic proximity Read ↗

The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

[Analysis of risk factors for thromboembolism in patients with JAK2V617F gene mutation positive myeloproliferative neoplasms].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.